PureTech Takes On Roche With Improved IPF Drug

Modified Version Of Esbriet Seems Safer

 
• By Ayisha Sharma

The firm’s lead candidate has shown strong tolerability in an early-stage trial for idiopathic pulmonary fibrosis, sparking hopes for registration-enabling studies and a streamlined development plan.      

Squiggly lines from start to finish line, a straight line from start to finish underneath. Streamlined concept.
PureTech Hopes To Piggyback Off Esbriet Data For A Smoother Filing • Source: Alamy

More from Clinical Trials

More from R&D